-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Board of Directors has appointed Aaron Berg, currently Amarin's Executive Vice President and President of the U.S. Business, as President and Chief Executive Officer (CEO). The appointment of Mr. Berg follows the resignation of Patrick Holt as ...

-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Board of Directors has appointed Aaron Berg, currently Amarin’s Executive Vice President and President of the U.S. Business, as President and Chief Executive Officer (CEO). The appointment of Mr. Berg follows the resignation of Patrick Holt as ...

-- Greek Ministry of Health approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in statin-treated adult patients with elevated triglycerides (≥ 150 mg/ml [≥ 1.7 mmol/l) and other high-risk characteristics as studied in REDUCE-IT1 -- -- Approval marks seventh national reimbursement of VAZKEPA® in Europe -- -- Vianex S.A., one of the leading pharmaceutical companies in Greece, will commercialize VAZKEPA® as Amarin's exclusive distributor in the country -- DUBLIN, Irela ...

-- Greek Ministry of Health approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in statin-treated adult patients with elevated triglycerides (≥ 150 mg/ml [≥ 1.7 mmol/l) and other high-risk characteristics as studied in REDUCE-IT1 -- -- Approval marks seventh national reimbursement of VAZKEPA® in Europe -- -- Vianex S.A., one of the leading pharmaceutical companies in Greece, will commercialize VAZKEPA® as Amarin’s exclusive distributor in the country -- DUBLIN, Irela ...

DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Patrick Holt, Amarin's president and chief executive officer, is scheduled to participate in fireside chat at the 2024 H.C. Wainwright 2nd Annual BioConnect Investor Conference. H.C. Wainwright 2nd Annual BioConnect Investor Conference (May 20th, 2024; NYC)Date/Time:May 20, 2024, 4:30 p.m. ETWebcast:https://journey.ct.events/view/a719062a-400f-406f-82d4-2463ef546624   The session ...

Amarin Corporation Plc (AMRN) reported first-quarter 2024 adjusted loss of 2 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 5 cents per share. The company had recorded an adjusted loss of 4 cents in the year-ago quarter.Total revenues were $56.5 million, which beat the Zacks Consensus Estimate of $51.0 million. However, revenues declined 34% from the year-ago quarter’s levels, owing to lower product revenues.Despite the better-than-expected results, shares of Amarin were ...

财务数据和关键指标变化 - 第一季度总收入为5650万美元,包括产品净收入5520万美元和许可及特许权使用费收入140万美元,相比2023年第一季度的8600万美元有所下降 [40] - 美国产品收入为4810万美元,相比2023年第一季度的8230万美元有所下降,主要是由于净售价下降受到仿制药竞争的影响 [41] - 欧洲产品净收入为190万美元,相比2023年第四季度增长35%,主要来自西班牙和英国的增长 [42] - 其他地区收入为520万美元,包括向加拿大、中国和中东地区的合作伙伴的供货收入 [42] - 毛利率为55%,2023年第一季度也为55%,剔除2023年第一季度的库存重组费用后毛利率为70% [43] 各条业务线数据和关键指标变化 - 美国业务虽然收入下降,但仍保持高盈利,公司将继续通过管理层、贸易和医疗事务团队来延长VASCEPA的生命周期 [16][18] - 欧洲业务方面,西班牙市场表现出色,第一季度患者人数增加91%,英国市场也有28%的增长,但仍属于较慢的市场 [12][13] - 公司正在积极推进欧洲主要市场的定价和报销进程,预计2024年将在至少5个新市场获得定价和报销决定 [14][15] 各个市场数据和关键指标变化 - 中国作为全球第二大心血管市场,公司合作伙伴Edding在2023年第三季度推出VASCEPA用于极高三酸甘油脂,2024年第一季度销售增长100% [19] - 加拿大市场HLS公司在不列颠哥伦比亚省获得主要私人支付人Pacific Blue Cross的公共准入和上市 [21] - 澳大利亚市场公司合作伙伴CSL Seqirus正在推进VAZKEPA报销的提交,时间表仍在轨道上 [21] 公司战略和发展方向及行业竞争 - 公司正专注于提高欧洲业务的价值和VASCEPA/VAZKEPA的患者使用,相信这是公司前进的最佳计划 [8] - 公司在欧洲成功延长了VAZKEPA的专利保护至2039年,这为公司和患者带来了额外价值 [11][25][26] - 公司正在采取更加聚焦的策略,包括针对高风险患者的细分市场定位、优化资源配置以及根据不同国家支付者需求调整价值主张 [60][61] - 公司正密切关注成本控制和现金管理,维持了7个季度的稳定现金头寸,并获得股东批准启动高达5000万美元的股票回购计划 [10][45][46] 管理层对经营环境和未来前景的评论 - 公司对欧洲市场前景充满信心,认为VAZKEPA的专利保护延长至2039年为公司和患者带来了额外价值 [11][49] - 美国业务虽然收入下降,但仍保持高盈利,公司将根据市场变化调整策略,包括未来可能推出授权仿制药 [16][18] - 公司看好中国等新兴市场的长期发展前景,认为这些市场存在巨大的未满足需求 [54][55] - 公司将继续专注于欧洲市场的发展,同时维持美国业务的盈利能力,为未来发展奠定基础 [64][65][66] 问答环节重要的提问和回答 问题1 **投资者提问** 什么时候可以看到中国市场的收入? [53] **Patrick Holt 回答** 中国是全球第二大心血管市场,公司合作伙伴Edding在2023年第三季度已经推出VASCEPA用于极高三酸甘油脂,2024年第一季度销售增长100%。此外,公司已提交心血管风险降低适应症,获得NMPA受理,一旦获批将有机会进入国家医保目录,从而带来更多的特许权使用费收入。 [54][55] 问题2 **投资者提问** 股票回购计划的进展如何?什么时候英国法院会批准?何时开始执行?公司计划回购多少股票? [56] **Patrick Holt 回答** 公司已获得股东大会批准实施高达5000万美元的股票回购计划,获得91%的支持。下一步是获得英国法院的批准,上周公司已向法院提交申请。一旦获得法院批准,公司将根据SEC和英国公司法开始执行回购。公司认为这是一个合理的资本使用方式,以向股东交付价值,同时公司现金头寸稳定,无债务负担。 [57][58] 问题3 **投资者提问** 公司在英国和欧洲的产品采用率为何较低?主要战略问题是什么?您对解决这些问题的信心如何? [59] **Patrick Holt 回答** 欧洲每个国家的市场准入和发布过程都非常复杂。去年公司在欧洲进行了新的领导层调整和战略转变,取得了一些进展。在西班牙市场,公司的新策略取得了很好的成效,第一季度患者人数增加91%。在英国市场,新的聚焦策略也开始显现成效,第一季度患者人数增加28%。总的来说,公司对欧洲市场前景充满信心,尤其是VAZKEPA专利延长至2039年,为未来的投资和发展奠定了基础。 [60][61][62]

Exhibit 99.1 Amarin Reports First Quarter 2024 Business Update and Financial Results -- New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 -- -- In Europe, ~35% Revenue Growth, ~65% In-Market Sales Growth Q1 '24 versus Q4 '23 Driven by Spain and the UK -- -- Current Cash Position of $308 Million; Remains Stable Over Seven Quarters -- -- Share Repurchase Program of up to $50 Million Approved by Shareholders; Repurchases Expected to Commence Foll ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-21392 Amarin Corporation plc (Exact Name of Registrant as Specified in its Charter) England and Wales Not applicable (State or Other Jurisdict ...

Amarin公司请愿 - Amarin公司支持一项向FDA提交的请愿，要求FDA关注和采取进一步行动来解决非标签使用芬布拉酸盐的问题[1] - 芬布拉酸盐与他汀类药物联合使用在减少心血管疾病风险方面无临床益处，但在2023年仍有超过1100万处方和超过100万患者使用了芬布拉酸盐[1] FDA请愿要求 - HealthyWomen提交的请愿要求FDA修改芬布拉酸盐药物标签，包括最新临床研究结果，以及进一步澄清FDA之前采取的立场[3]